Robyn Karnauskas
Stock Analyst at Truist Securities
(1.95)
# 3,075
Out of 5,179 analysts
177
Total ratings
43.14%
Success rate
-0.21%
Average return
Main Sectors:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,038 → $1,182 | $878.24 | +34.59% | 6 | Nov 19, 2025 | |
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.27 | +205.81% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $348.77 | -14.56% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $58.54 | +11.04% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $119.63 | -8.05% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $134.25 | -38.18% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $209.40 | +0.29% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.32 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $183.84 | +84.94% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $0.56 | +4,580.47% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $1.63 | +329.45% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $737.71 | +53.85% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.51 | +562.25% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.78 | +223.74% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $26.52 | -13.27% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $23.98 | +100.17% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $20.28 | +146.55% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $433.07 | +17.30% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $27.04 | +33.14% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $66.13 | -62.20% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.26 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $54.14 | +158.59% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $1.40 | +2,142,757.14% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.17 | +498.29% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $14.77 | +272.38% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $7.79 | +4,007.83% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $37.00 | -59.46% | 5 | Aug 9, 2022 |
Eli Lilly and Company
Nov 19, 2025
Maintains: Buy
Price Target: $1,038 → $1,182
Current: $878.24
Upside: +34.59%
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.27
Upside: +205.81%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $348.77
Upside: -14.56%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $58.54
Upside: +11.04%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $119.63
Upside: -8.05%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $134.25
Upside: -38.18%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $209.40
Upside: +0.29%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.32
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $183.84
Upside: +84.94%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $0.56
Upside: +4,580.47%
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.63
Upside: +329.45%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $737.71
Upside: +53.85%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.51
Upside: +562.25%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.78
Upside: +223.74%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $26.52
Upside: -13.27%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $23.98
Upside: +100.17%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $20.28
Upside: +146.55%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $433.07
Upside: +17.30%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $27.04
Upside: +33.14%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $66.13
Upside: -62.20%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.26
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $54.14
Upside: +158.59%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $1.40
Upside: +2,142,757.14%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.17
Upside: +498.29%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $14.77
Upside: +272.38%
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $7.79
Upside: +4,007.83%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $37.00
Upside: -59.46%